Literature DB >> 22611469

α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.

David S Garlick, Jing Li, Brian Sansoucy, Tao Wang, Leeanne Griffith, Tj Fitzgerald, Julie Butterfield, Bridget Charbonneau, Shelia M Violette, Paul H Weinreb, Timothy L Ratliff, Chun-Peng Liao, Pradip Roy-Burman, Michele Vietri, Jane B Lian, Gary S Stein, Dario C Altieri, Lucia R Languino.   

Abstract

Chronic inflammation is proposed to prime the development of prostate cancer. However, the mechanisms of prostate cancer initiation and development are not completely understood. The α(v)β(6) integrin has been shown to play a role in epithelial development, wound healing and some epithelial cancers [1, 2]. Here, we investigate the expression of α(v)β(6) in mouse models of prostatic inflammation and prostate cancer to establish a possible relationship between inflammation of the prostate, α(v)β(6) expression and the progression of prostate cancer. Using immunohistochemical techniques, we show expression of α(v)β(6) in two in vivo mouse models; the Pten(pc)-/- model containing a prostate- specific Pten tumor suppressor deletion that causes cancer, and the prostate ovalbumin-expressing transgenic (POET) inflammation mouse model. We show that the α(v)β(6) integrin is induced in prostate cancer and inflammation in vivo in these two mouse models. α(v)β(6) is expressed in all the mice with cancer in the Pten(pc-/-) model but not in age-matched wild-type mice. In the POET inflammation model, α(v)β(6) is expressed in mice injected with activated T-cells, but in none of the control mice. In the POET model, we also used real time PCR to assess the expression of Transforming Growth Factor Beta 1 (TGFβ1), a factor in inflammation that is activated by α(v)β(6). In conclusion, through in vivo evidence, we conclude that α(v)β(6) integrin may be a crucial link between prostatic inflammation and prostatic adenocarcinoma.

Entities:  

Keywords:  Akt; PIN lesion; Prostate cancer; TGFβ1; chronic inflammation; αvβ6 integrin

Year:  2012        PMID: 22611469      PMCID: PMC3353537     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  48 in total

1.  Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes.

Authors:  Paul H Weinreb; Kenneth J Simon; Paul Rayhorn; William J Yang; Diane R Leone; Brian M Dolinski; Bradley R Pearse; Yukako Yokota; Hisaaki Kawakatsu; Amha Atakilit; Dean Sheppard; Shelia M Violette
Journal:  J Biol Chem       Date:  2004-02-11       Impact factor: 5.157

Review 2.  Alphavbeta6 integrin in wound healing and cancer of the oral cavity.

Authors:  G J Thomas; M L Nyström; J F Marshall
Journal:  J Oral Pathol Med       Date:  2006-01       Impact factor: 4.253

3.  Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse.

Authors:  Kyungmin Hahm; Matvey E Lukashev; Yi Luo; William J Yang; Brian M Dolinski; Paul H Weinreb; Kenneth J Simon; Li Chun Wang; Diane R Leone; Roy R Lobb; Donald J McCrann; Normand E Allaire; Gerald S Horan; Agnes Fogo; Raghu Kalluri; Charles F Shield; Dean Sheppard; Humphrey A Gardner; Shelia M Violette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

4.  Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.

Authors:  S Zha; W R Gage; J Sauvageot; E A Saria; M J Putzi; C M Ewing; D A Faith; W G Nelson; A M De Marzo; W B Isaacs
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 5.  The structure of cell-adhesion molecules.

Authors:  M J Humphries; P Newham
Journal:  Trends Cell Biol       Date:  1998-02       Impact factor: 20.808

Review 6.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

7.  Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment.

Authors:  S Madaan; P D Abel; K S Chaudhary; R Hewitt; M A Stott; G W Stamp; E N Lalani
Journal:  BJU Int       Date:  2000-10       Impact factor: 5.588

8.  Keratinocytes in human wounds express alpha v beta 6 integrin.

Authors:  K Haapasalmi; K Zhang; M Tonnesen; J Olerud; D Sheppard; T Salo; R Kramer; R A Clark; V J Uitto; H Larjava
Journal:  J Invest Dermatol       Date:  1996-01       Impact factor: 8.551

9.  p27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma.

Authors:  M Fornaro; G Tallini; D Q Zheng; W M Flanagan; M Manzotti; L R Languino
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  12 in total

1.  The αvβ6 integrin is transferred intercellularly via exosomes.

Authors:  Carmine Fedele; Amrita Singh; Brad J Zerlanko; Renato V Iozzo; Lucia R Languino
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

2.  Development of animal models underlining mechanistic connections between prostate inflammation and cancer.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2013-02-10

3.  Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2.

Authors:  Anindita Dutta; Jing Li; Huimin Lu; Jacqueline Akech; Jitesh Pratap; Tao Wang; Brad J Zerlanko; Thomas J FitzGerald; Zhong Jiang; Ruth Birbe; John Wixted; Shelia M Violette; Janet L Stein; Gary S Stein; Jane B Lian; Lucia R Languino
Journal:  Cancer Res       Date:  2014-01-02       Impact factor: 12.701

4.  αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.

Authors:  Anindita Dutta; Jing Li; Carmine Fedele; Aejaz Sayeed; Amrita Singh; Shelia M Violette; Thomas D Manes; Lucia R Languino
Journal:  Biochem J       Date:  2015-03-15       Impact factor: 3.857

5.  αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Authors:  Huimin Lu; Tao Wang; Jing Li; Carmine Fedele; Qin Liu; Jianzhong Zhang; Zhong Jiang; Dhanpat Jain; Renato V Iozzo; Shelia M Violette; Paul H Weinreb; Roger J Davis; Daniel Gioeli; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino
Journal:  Cancer Res       Date:  2016-07-22       Impact factor: 12.701

6.  Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer.

Authors:  Louisa C E Windus; Tristan T Glover; Vicky M Avery
Journal:  Mol Cancer       Date:  2013-09-30       Impact factor: 27.401

7.  Identification of functional pathways associated with the conditional ablation of serum response factor in Dstncorn1 mice.

Authors:  Yanan Huo; Xin Xie; Bo Jiang
Journal:  Mol Med Rep       Date:  2016-12-05       Impact factor: 2.952

8.  Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression.

Authors:  Fabio Quaglia; Shiv Ram Krishn; Yanqing Wang; David W Goodrich; Peter McCue; Andrew V Kossenkov; Amy C Mandigo; Karen E Knudsen; Paul H Weinreb; Eva Corey; William K Kelly; Lucia R Languino
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

9.  RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.

Authors:  Mark Sutherland; Andrew Gordon; Steven D Shnyder; Laurence H Patterson; Helen M Sheldrake
Journal:  Cancers (Basel)       Date:  2012-10-26       Impact factor: 6.639

10.  PCaAnalyser: a 2D-image analysis based module for effective determination of prostate cancer progression in 3D culture.

Authors:  Md Tamjidul Hoque; Louisa C E Windus; Carrie J Lovitt; Vicky M Avery
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.